Board Member
Tandem Diabetes Care Inc (TNDM)Equibles does not estimate personal net worth.
Get an email with a short summary when Tandem Diabetes Care Inc publishes a filing, an earnings call transcript or a press release.
Get TNDM alertsJohn Sheridan is recorded as Board Member and CEO at Tandem Diabetes Care Inc (TNDM). The newest filing on record that lists John Sheridan as Board Member and CEO at Tandem Diabetes Care Inc (TNDM) is dated April 7, 2026. Tandem Diabetes Care Inc reported in an 8-K filed May 21, 2026 that John Sheridan was appointed director, effective May 20, 2026. The proxy statement of Tandem Diabetes Care Inc reports total compensation of $6,378,515 for John Sheridan in fiscal 2022, including a base salary of $710,700. Disclosed compensation is on record for 6 fiscal years. John Sheridan has spoken on 26 earnings calls and 1 other investor event across 1 company, most recently for Tandem Diabetes Care Inc on August 6, 2026. Tandem Diabetes Care Inc is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Tandem Diabetes Care Inc includes Kim Blickenstaff (Chairman), Rebecca Robertson (Chairman and Board Member), Leigh Vosseller (CFO and Board Member) and 7 others.
“The stockholders elected nine directors by the following votes:”
“Before we close, I want to recognize the entire Tandem team for the focus and care you continue to bring to work every day. Your efforts are helping us advance our priorities, support our customers and healthcare care providers, and sustained progress across the business.”
“We had, you guys probably know, we received CE mark for our pregnancy indication just a few days before the conference started, and we had a symposium on Saturday morning into which we actually went through and presented the data to a pretty large group of doctors, and that went over very well.”
“In the first quarter of 2026, we delivered strong financial and operational performance, setting the stage for another successful year. This momentum reflects the dedication of our team and our commitment to our strategic objectives.”
“2025 was a defining year for Tandem, where we surpassed the milestone of $1 billion in sales, while delivering our mission to provide new innovations, improved outcomes, and a revolutionary experience to nearly half a million customers worldwide.”
“In the third quarter, we achieved significant strategic milestones and delivered record Q3 sales. This year has represented a period of transformation for Tandem, and we are doing the right thing to position our company for success.”
Start not stated–present
Last confirmed April 7, 2026
Start not stated–present
Last confirmed April 7, 2026
Medical Devices · Healthcare
Board Member, CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Tandem Diabetes Care Inc (TNDM) | President and Chief Executive Officer | $710,700 | $6,378,515 |
| 2021 | Tandem Diabetes Care Inc (TNDM) | President and Chief Executive Officer | $690,000 | $5,739,882 |
| 2020 | Tandem Diabetes Care Inc (TNDM) | President and Chief Executive Officer | $600,000 | $3,790,739 |
| 2019 | Tandem Diabetes Care Inc (TNDM) | President and Chief Executive Officer | $500,000 | $10,560,937 |
| 2018 | Tandem Diabetes Care Inc (TNDM) | President and Chief Executive Officer | $386,250 | $1,937,417 |
| 2017 | Tandem Diabetes Care Inc (TNDM) | President and Chief Executive Officer | $375,000 | $596,131 |
